Patten Group Inc. lessened its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.5% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 8,463 shares of the company’s stock after selling 400 shares during the quarter. Patten Group Inc.’s holdings in IDEXX Laboratories were worth $2,210,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. ARP Americas LP lifted its stake in shares of IDEXX Laboratories by 5.0% during the 3rd quarter. ARP Americas LP now owns 2,100 shares of the company’s stock worth $571,000 after buying an additional 100 shares during the last quarter. National Pension Service increased its position in IDEXX Laboratories by 5.5% during the third quarter. National Pension Service now owns 111,022 shares of the company’s stock worth $30,190,000 after acquiring an additional 5,794 shares during the period. Public Employees Retirement System of Ohio increased its position in IDEXX Laboratories by 6.8% during the third quarter. Public Employees Retirement System of Ohio now owns 66,896 shares of the company’s stock worth $18,191,000 after acquiring an additional 4,274 shares during the period. Cubist Systematic Strategies LLC increased its position in IDEXX Laboratories by 219.0% during the second quarter. Cubist Systematic Strategies LLC now owns 9,597 shares of the company’s stock worth $2,642,000 after acquiring an additional 6,589 shares during the period. Finally, Brasada Capital Management LP increased its position in IDEXX Laboratories by 1.6% during the third quarter. Brasada Capital Management LP now owns 18,546 shares of the company’s stock worth $5,043,000 after acquiring an additional 287 shares during the period. Institutional investors own 86.41% of the company’s stock.

NASDAQ:IDXX traded up $1.70 during mid-day trading on Tuesday, reaching $283.99. 303,630 shares of the company’s stock were exchanged, compared to its average volume of 424,066. IDEXX Laboratories, Inc. has a one year low of $189.69 and a one year high of $294.57. The firm has a market capitalization of $24.16 billion, a PE ratio of 66.66 and a beta of 0.72. The business’s fifty day simple moving average is $259.67 and its two-hundred day simple moving average is $271.25. The company has a debt-to-equity ratio of 3.76, a quick ratio of 0.80 and a current ratio of 1.12.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.10. IDEXX Laboratories had a net margin of 17.99% and a return on equity of 405.71%. The business had revenue of $605.30 million for the quarter, compared to analyst estimates of $597.09 million. During the same period last year, the firm earned $1.05 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 11.0% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 4.76 EPS for the current year.

In other IDEXX Laboratories news, VP Giovani Twigge sold 14,750 shares of the firm’s stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $250.51, for a total value of $3,695,022.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Jonathan W. Ayers sold 62,097 shares of the firm’s stock in a transaction dated Monday, November 4th. The shares were sold at an average price of $279.57, for a total transaction of $17,360,458.29. The disclosure for this sale can be found here. Over the last three months, insiders sold 116,130 shares of company stock worth $31,118,453. Insiders own 2.70% of the company’s stock.

IDXX has been the topic of a number of recent research reports. Guggenheim set a $310.00 price target on shares of IDEXX Laboratories and gave the stock a “buy” rating in a research report on Friday, November 1st. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $278.00 price target on the stock in a research report on Friday, January 3rd. BidaskClub raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, ValuEngine lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. IDEXX Laboratories presently has an average rating of “Buy” and a consensus price target of $291.14.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: What are the benefits of a portfolio tracker?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.